#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic lymphocytic leukaemia refractory Chronic graft versus host disease in intestine B-cell lymphoma refractory Neurodermatitis Cholangitis sclerosing Infantile spasms Aspergillus infection Chronic lymphocytic leukaemia recurrent Synovial sarcoma recurrent Oesophageal achalasia Hyperchylomicronaemia Hyperinsulinaemic hypoglycaemia Loss of consciousness Henoch-Schonlein purpura Cytokine release syndrome More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent Andersen-Tawil syndrome – Diagnostics Angiosarcoma non-metastatic – Life with Disease Nephrotic syndrome – Basic Information Kearns-Sayre syndrome – Treatment Ewing’s sarcoma – Basic Information Hereditary motor and sensory neuropathy Marfan’s syndrome – Basic Information Undifferentiated sarcoma Optic glioma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Efzofitimod Micafungin RLY-2608 Tenofovir Disoproxil Silibinin Tuparstobart Phenol, Liquefied Avb-101 Antithrombin Iii Human Glucose, Anhydrous Abatacept Ict01 Spiramycin Paeonol GSKVX000000070248 Sodium Laurilsulfate Lurasidone Resiquimod Sulfate SUMATRIPTAN VG801-2 More therapies…

    Learn about Your Condition

    Transplant rejection Somatic symptom disorder Nephrogenic anaemia Cirrhosis alcoholic Dyslipidaemia Thymoma malignant Ejection fraction normal Anal cancer recurrent Urinary incontinence Sarcoma metastatic Post procedural infection Major depression Ocular myasthenia Lung neoplasm malignant Clostridium difficile colitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    • Tislelizumab
    France

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Ipilimumab
    Austria Belgium Czechia Denmark Finland France +5

  • Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Tuvusertib
    France

  • Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France

  • Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Hormone-refractory prostate cancer
    • Lymphoma
    Investigated Drugs:
    • Enzalutamide
    • Tulmimetostat
    France Italy Poland Spain

  • Comparison of Cyclophosphamide and Doxorubicin for Treatment of Advanced or Metastatic Soft Tissue Sarcoma in Patients Age 65 and Older

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Soft tissue sarcoma
    Investigated Drugs:
    • Cyclophosphamide
    • Dexrazoxane Hydrochloride
    • Doxorubicin
    France

  • Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Anastrozole
    • Avutometinib
    • Defactinib
    Belgium Denmark France Germany Ireland Italy +3

  • Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Nephroblastoma
    Investigated Drugs:
    • Carboplatin
    • Dactinomycin
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • Study of Atezolizumab After Chemo-radiotherapy for Patients with Muscle-invasive Bladder Cancer Not Eligible for Radical Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    France

  • Study on Darolutamide and Triptorelin for Patients with Localized High-Risk Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Darolutamide
    • Triptorelin
    France Spain
Previous Page
1 … 7 8 9 10 11 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!